Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GSK plc
GSK
$47.82
Name : GSK plc
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $95,853,740,032.00
EPSttm : 2.87
finviz dynamic chart for GSK
GSK plc
$47.82
1.56%
$0.76
GSK — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.81

Margin Of Safety %

37

Put/Call OI Ratio

0.64

EPS Next Q Diff

EPS Last/This Y

1.05

EPS This/Next Y

0.2

Price

47.82

Target Price

56.57

Analyst Recom

2

Performance Q

-8.74

Upside

-22.0%

Beta

0.3

Ticker: GSK




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21GSK50.060.580.2066069
2026-10-22GSK51.210.550.2170275
2026-10-23GSK50.750.540.8471802
2026-10-26GSK51.120.570.7268659
2026-10-27GSK50.990.572.1569350
2026-10-28GSK48.780.580.3470471
2026-10-29GSK48.670.591.0371486
2026-10-30GSK49.520.600.5271860
2026-11-02GSK49.130.630.8466601
2026-11-03GSK48.740.630.3567296
2026-11-04GSK51.160.632.2767541
2026-11-05GSK50.410.630.3268300
2026-11-06GSK50.330.630.1369308
2026-11-09GSK51.540.630.2867902
2026-11-10GSK51.240.630.1268452
2026-11-11GSK50.60.610.7470518
2026-11-12GSK50.640.610.0570707
2026-11-13GSK50.460.640.3869025
2026-11-16GSK50.420.640.4768911
2026-11-17GSK49.240.640.5569789
2026-11-18GSK48.580.640.3570456
2026-11-19GSK47.820.641.0170518
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21GSK50.64-8.84513.14.72
2026-10-22GSK51.21-8.84517.04.72
2026-10-23GSK50.75-8.84155.94.72
2026-10-26GSK51.10-8.84430.74.72
2026-10-27GSK50.97-8.84370.04.73
2026-10-28GSK48.76-8.83930.24.73
2026-10-29GSK48.68-8.84962.44.73
2026-10-30GSK49.51-8.85062.44.73
2026-11-02GSK49.137.14829.44.78
2026-11-03GSK48.745.54684.54.76
2026-11-04GSK51.155.55321.24.76
2026-11-05GSK50.405.54677.84.76
2026-11-06GSK50.325.54884.24.76
2026-11-09GSK51.545.55223.84.76
2026-11-10GSK51.245.54831.54.76
2026-11-11GSK50.645.54756.94.76
2026-11-12GSK50.645.55000.04.76
2026-11-13GSK50.455.54884.64.76
2026-11-16GSK50.425.54858.14.76
2026-11-17GSK49.245.54603.44.76
2026-11-18GSK48.585.54699.54.76
2026-11-19GSK47.825.54660.74.76
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21GSK0.00-2.060.74
2026-10-22GSK0.00-2.060.74
2026-10-23GSK0.00-2.060.74
2026-10-26GSK0.00-2.070.74
2026-10-27GSK0.00-2.070.73
2026-10-28GSK0.00-2.070.73
2026-10-29GSK0.00-2.070.73
2026-10-30GSK0.00-2.070.73
2026-11-02GSK0.00-1.990.73
2026-11-03GSK0.00-1.990.73
2026-11-05GSK0.00-1.990.73
2026-11-06GSK0.00-1.990.73
2026-11-09GSK0.00-2.050.73
2026-11-10GSK0.00-2.050.73
2026-11-11GSK0.00-2.050.81
2026-11-12GSK0.00-2.050.81
2026-11-13GSK0.00-2.050.81
2026-11-16GSK0.00-2.620.81
2026-11-17GSK0.00-2.620.81
2026-11-18GSK0.00-2.620.81
2026-11-19GSK0.00-2.620.81
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

1.47

Avg. EPS Est. Current Quarter

0.74

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-2.62

Beta

0.3

Average Sales Estimate Current Quarter

11616

Average Sales Estimate Next Quarter

Fair Value

65.48

Quality Score

90

Growth Score

80

Sentiment Score

22

Actual DrawDown %

22.5

Max Drawdown 5-Year %

-39.3

Target Price

56.57

P/E

16.67

Forward P/E

9.62

PEG

2.73

P/S

2.13

P/B

3.85

P/Free Cash Flow

10.21

EPS

2.87

Average EPS Est. Cur. Y​

4.76

EPS Next Y. (Est.)

4.96

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.99

Relative Volume

0.83

Return on Equity vs Sector %

-3.3

Return on Equity vs Industry %

-11.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

4660.7
◆ GSK Healthcare
$47.83
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
13/25
Volume
7/15
Valuation
18/20
TP/AR
1/10
Options
5/10
RSI
38.9
Range 1M
9.2%
🚀
Momentum Growth
Ride accelerating trends
N/A
24 /100
WEAK
Momentum
4/25
Growth
8/30
Estimates
6/20
Inst/Vol
1/15
Options
5/10
EPS Yr
1.7%
EPS NY
4%
52W%
12.4%
💎
Long-Term Value
Quality companies, undervalued
49 /100
WEAK
🟢 BUY +32.1% upside
Quality
22/30
Valuation
15/30
Growth
6/25
Stability
2/10
LT Trend
4/5
Upside
+32.1%
Quality
90
MoS
37%
GSK — P/E HistoricalDrug Manufacturers - General
GSK plc
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 66841
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
GSK

Latest News

—
Caricamento notizie per GSK…
stock quote shares GSK – GlaxoSmithKline plc Stock Price stock today
news today GSK – GlaxoSmithKline plc stock forecast ,stock prediction 2023 2024 2025
marketwatch GSK – GlaxoSmithKline plc yahoo finance google finance
stock history GSK – GlaxoSmithKline plc invest stock market
stock prices GSK premarket after hours
ticker GSK fair value insiders trading